The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature

Anees ur Rehman (), Mohamed Azmi Ahmad Hassali (), Sohail Ayaz Muhammad (), Sabariah Noor Harun (), Shahid Shah () and Sameen Abbas ()
Additional contact information
Anees ur Rehman: University Sains Malaysia
Mohamed Azmi Ahmad Hassali: University Sains Malaysia
Sohail Ayaz Muhammad: University Sains Malaysia
Sabariah Noor Harun: University Sains Malaysia
Shahid Shah: Government College University
Sameen Abbas: Quaid e Azam University Islamabad

The European Journal of Health Economics, 2020, vol. 21, issue 2, No 3, 194 pages

Abstract: Abstract Objectives To find the economic burden of COPD and to identify the key cost drivers in the management of COPD patients across different European countries. Background COPD is a major cause of mortality and morbidity and is associated with considerable economic burden on the individual and society. It limits the daily activities and working ability of the patients. Methodology We conducted a systematic search of PUBMED, SCIENCE DIRECT, Cochrane CENTRAL, SCOPUS, Google Scholar and SAGE Premier Databases to find scientific research articles evaluating the cost of COPD management from patient and societal perspective. Results Estimated per patient per year direct cost in Norway, Denmark, Germany, Italy, Sweden, Greece, Belgium, and Serbia was €10,701, €9580, €7847, €7448, €7045, €2896, €1963, and €2047, respectively. Annual per patient cost of work productivity loss was highest in Germany as €5735 and lowest in Greece as €998. It was estimated as €4824, €2033 and €1298 in Bulgaria, Denmark and Sweden, respectively. Several factors found associated with increasing cost of COPD management that include but not limited to late diagnosis, severity of disease, frequency of exacerbation, hospital readmissions, non-adherence to the therapy and exposure to COPD risk factors. Conclusion Minimizing the COPD exacerbations and controlling the worsening of symptoms may potentially reduce the cost of COPD management at any stage.

Keywords: COPD; Pharmacoeconomics; Direct and indirect cost; Economic burden; Europe; Systematic review (search for similar items in EconPapers)
JEL-codes: H51 I18 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://link.springer.com/10.1007/s10198-019-01119-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:21:y:2020:i:2:d:10.1007_s10198-019-01119-1

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-019-01119-1

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().